Founder TET2 (22.2%) and TP53 (22.2%) mutations were the most common in CH-derived disease, followed by those in PPM1D (11.1%), BCOR/L1 (11.1%), DNTM3A (11.1%), SMC1A (11.1%) and ZRSR2 (11.1%) genes (Fig. 4B). This evidence concerns the gene TP53 and cyclic hematopoiesis.